Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Lamictal with Slower Titration in Epilepsy
NCT00395694Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2006
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lamotrigine in epilepsy, sponsored by GSK. Primary endpoint: Number of Participants With Any Rash Event (Including Stevens-Johnson Syndrome [SJS] and Any Other Serious Drug Eruption) During the Initial 8 Weeks of Study Treatment. Started Aug 2006; status: completed.
02
Drugs
lamotrigine
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT00395694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00395694.